Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × Everolimus × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Carcinoma, Renal Cell 7 Neuroendocrine Tumors 6 Tuberous Sclerosis 3 Triple Negative Breast Neoplasms 3 von Hippel-Lindau Disease 2 Recurrence 2 Neoplasm Metastasis 2 Glioma 2 Diffuse Intrinsic Pontine Glioma 2 Carcinoma, Hepatocellular 2 Adenoma, Islet Cell 2 Waldenstrom Macroglobulinemia 1 Vascular Malformations 1 Unilateral Breast Neoplasms 1 Thyroid cancer, Hurthle cell 1 Thymus Neoplasms 1 Skin Neoplasms 1 Seizures 1 Sarcoma 1 Pheochromocytoma 1 Paraganglioma 1 Ovarian Neoplasms 1 Nevus 1 Neoplasms, Plasma Cell 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Meningioma 1

Interventions

lutetium Lu 177 dotatate 5 Magnetic Resonance Spectroscopy 5 Specimen Handling 4 gallium Ga 68 dotatate 3 pembrolizumab 2 abemaciclib 2 Radiosurgery 2 Nivolumab 2 Ipilimumab 2 Ga(III)-DOTATOC 2 Elasticity Imaging Techniques 2 CTLA-4 Antigen 2 ribociclib 1 regorafenib 1 olaparib 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 capivasertib 1 cabozantinib 1 auricularum 1 X-Rays 1 Tablets 1 TIC10 compound 1 Surveys and Questionnaires 1 Sunitinib 1 Spinal Puncture 1 Saline Solution 1 Restraint, Physical 1 Radiation Dose Hypofractionation 1 Protons 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06955169 2026-04-21

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Recruiting

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡